AAA Reports 37% growth in sales for the 3th quarter of 2015
- Reported an increase in year -over-year sales of approximately 37% for Q3 2015 compared toQ3 2014
- Reported an increase in year-over-year sales of approximately 32% for the first nine months of 2015 compared to the first nine months of 2014
- Announced positive results from Phase 3 NETTER-1 study, evaluating lead drug candidate Lutathera in patients with advanced midgut neuroendocrine tumors
- Obtained two Marketing Authorizations in France for FCholine and FDopa
- Received FDA Priority Review for Somakit-TATE New Drug Application
- Submitted MA application to EMA for Somakit-TOC
Read the press release
Diary - News
All news AAA Reports 37% growth in sales for the 3th quarter of 2015 